左心室心肌致密化不全心肌病的临床遗传学与结局
该注册研究随访中位61个月,分析95例左心室心肌致密化不全(LVNC)患者(68例无亲缘关系先证者及27例受累亲属,明确的家族性LVNC占23.5%),通过心脏表型、分子生物标志物和外显子测序进行临床与遗传特征分析。LVNC患者心血管事件显著多于年龄匹配的非缺血性扩张型心肌病患者(风险比=2.481,P=0.002)。按ACMG指南严格分类,TTN、LMNA和MYBPC3是最常见的致病基因,其中13例携带致病性TTN截短变异(比值比=40.7,置信区间=21.6-76.6,P<0.0001,剪接百分比76-100%);RBM20新变异p.R634L与LVNC共分离,导致titin错误剪接。
要点
- 症状性LVNC临床病程可能严重,心血管事件风险高于年龄匹配的非缺血性扩张型心肌病患者。
- TTN、LMNA和MYBPC3是LVNC最常见致病基因,TTN截短变异显著富集。
- 核蛋白Lamin A/C和RBM20的致病性变异与更差结局相关。
核心结论
- 症状性LVNC的临床病程可能严重,心血管事件风险显著高于年龄匹配的非缺血性扩张型心肌病患者。
- TTN、LMNA和MYBPC3是LVNC最常见致病基因,每第四例患者存在titin相关病理机制。
- 核蛋白Lamin A/C和RBM20的致病性变异与更差结局相关。
研究设计与样本
- 注册研究,随访中位61个月,纳入95例LVNC患者(68例无亲缘关系先证者及27例受累亲属,明确的家族性LVNC占23.5%)。
- 采用心脏表型、分子生物标志物和外显子测序进行分析,并按ACMG指南进行严格遗传分类。
主要发现
- LVNC患者心血管事件显著多于年龄匹配的非缺血性扩张型心肌病患者(风险比=2.481,P=0.002)。
- TTN、LMNA和MYBPC3是最常见致病基因,13例携带致病性TTN截短变异(比值比=40.7,置信区间=21.6-76.6,P<0.0001,剪接百分比76-100%)。
- RBM20新变异p.R634L在RS结构域与LVNC共分离,导致titin错误剪接(经心脏组织RNA测序、蛋白分析和功能剪接报告基因试验证实)。
关键数值与推荐
- 明确的家族性LVNC占23.5%(95例中23.5%)。
- LVNC患者心血管事件风险比=2.481(P=0.002),对照为年龄匹配的非缺血性扩张型心肌病患者。
- TTN截短变异比值比=40.7(置信区间=21.6-76.6,P<0.0001),剪接百分比76-100%。
临床怎么用
- 对症状性LVNC患者应考虑遗传咨询,关注TTN、LMNA、MYBPC3及RBM20等基因。
- 核蛋白Lamin A/C和RBM20致病性变异携带者可能需更密切随访,因其与更差结局相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In this study, we aimed to clinically and genetically characterize LVNC patients and investigate the prevalence of variants in known and novel LVNC disease genes. INTRODUCTION: Left ventricular non-compaction cardiomyopathy (LVNC) is an increasingly recognized cause of heart failure, arrhythmia, thromboembolism, and sudden cardiac death. We sought here to dissect its genetic causes, phenotypic presentation and outcome. METHODS AND RESULTS: In our registry with follow-up of in the median 61 months, we analysed 95 LVNC patients (68 unrelated index patients and 27 affected relatives; definite familial LVNC = 23.5%) by cardiac phenotyping, molecular biomarkers and exome sequencing. Cardiovascular events were significantly more frequent in LVNC patients compared with an age-matched group of patients with non-ischaemic dilated cardiomyopathy (hazard ratio = 2.481, P = 0.002). Stringent genetic classification according to ACMG guidelines revealed that TTN, LMNA, and MYBPC3 are the most prevalent disease genes (13 patients are carrying a pathogenic truncating TTN variant, odds ratio = 40.7, Confidence interval = 21.6-76.6, P < 0.0001, percent spliced in 76-100%). We also identified novel candidate genes for LVNC. For RBM20, we were able to perform detailed familial, molecular and functional studies. We show that the novel variant p.R634L in the RS domain of RBM20 co-segregates with LVNC, leading to titin mis-splicing as revealed by RNA sequencing of heart tissue in mutation carriers, protein analysis, and functional splice-reporter assays. CONCLUSION: Our data demonstrate that the clinical course of symptomatic LVNC can be severe. The identified pathogenic variants and distribution of disease genes-a titin-related pathomechanism is found in every fourth patient-should be considered in genetic counselling of patients. Pathogenic variants in the nuclear proteins Lamin A/C and RBM20 were associated with worse outcome.
引用
- Sedaghat-Hamedani F, Haas J, Zhu F, et al. Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. Eur Heart J. 2017. PMID: 29029073. doi:10.1093/eurheartj/ehx545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。